Page last updated: 2024-12-11

1-ethyl-N-[[1-(phenylmethyl)-2-benzimidazolyl]methyl]-5-benzimidazolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-ethyl-N-[[1-(phenylmethyl)-2-benzimidazolyl]methyl]-5-benzimidazolamine is a complex organic molecule, often abbreviated as **compound A** for research purposes. It's important to understand that this compound is likely **not an established drug or therapeutic** but rather a **research compound** synthesized and studied in laboratories.

**Why might this compound be important for research?**

Let's break down the structure and potential implications:

* **Benzimidazole Moieties:** This compound features two benzimidazole rings. Benzimidazoles are known to possess various pharmacological activities, including:
* **Antiviral properties:** They are used in antiviral medications, particularly for the treatment of viral infections like HIV.
* **Anti-inflammatory activity:** Some benzimidazoles exhibit anti-inflammatory properties, which are relevant in various diseases.
* **Anthelmintic activity:** Benzimidazoles are used as antiparasitic drugs, particularly for treating roundworms.

* **Alkyl Substitutions:** The compound contains various alkyl groups (ethyl, phenylmethyl) attached to the benzimidazole rings. These modifications could potentially influence:
* **Pharmacokinetic properties:** How the compound is absorbed, distributed, metabolized, and eliminated in the body.
* **Pharmacodynamic properties:** How the compound interacts with target proteins or biological pathways.

* **Potential Biological Target:** While the exact target is unknown, the structure suggests it might interact with proteins involved in:
* **Viral replication:** The presence of benzimidazoles points towards a potential antiviral target.
* **Inflammation:** The compound's structure suggests it could modulate inflammatory pathways.
* **Other biological processes:** It's possible that this compound could have activity against other biological targets not yet identified.

**Overall:**

1-ethyl-N-[[1-(phenylmethyl)-2-benzimidazolyl]methyl]-5-benzimidazolamine is a complex molecule likely synthesized for research purposes. Its structure suggests potential therapeutic applications due to the presence of benzimidazole rings, which are known to possess various pharmacological activities.

**Important Note:** It's crucial to understand that this compound is **not a confirmed drug** and might not be safe for human use. Research on this compound likely involves **preliminary studies** to understand its potential effects and explore possible therapeutic applications. Further research is needed to determine its safety, efficacy, and potential clinical uses.

Cross-References

ID SourceID
PubMed CID9549753
CHEMBL ID1453421
CHEBI ID112262

Synonyms (14)

Synonym
EU-0056934
smr000113993
MLS000550495
n-[(1-benzyl-1h-benzimidazol-2-yl)methyl]-n-(1-ethyl-1h-benzimidazol-5-yl)amine
AKOS001794827
CHEBI:112262
HMS1622L09
CCG-127836
HMS2333M06
CHEMBL1453421
1-ethyl-n-[[1-(phenylmethyl)-2-benzimidazolyl]methyl]-5-benzimidazolamine
Q27192365
n-[(1-benzyl-1h-1,3-benzodiazol-2-yl)methyl]-1-ethyl-1h-1,3-benzodiazol-5-amine
n-[(1-benzylbenzimidazol-2-yl)methyl]-1-ethylbenzimidazol-5-amine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency5.35820.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency1.00000.01846.806014.1254AID624417
BRCA1Homo sapiens (human)Potency35.48130.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency2.18530.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency17.58860.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency15.84890.180013.557439.8107AID1460
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency39.81070.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency3.54810.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency12.58930.316212.443531.6228AID903
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.92000.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency2.81840.00022.621531.4954AID485297
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency17.78280.075215.225339.8107AID485360
gemininHomo sapiens (human)Potency5.01190.004611.374133.4983AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency7.07950.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.20 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]